小剂量凝血因子输注治疗血友病急性关节出血的疗效分析
|
摘要
目的分析小剂量凝血因子输注治疗血友病急性关节出血的疗效。方法 85例血友病急性关节出血患儿,均行小剂量凝血因子输注治疗。比较治疗前、治疗后1年出血程度、视觉模拟评分法(VAS)评分、生活质量。结果治疗后,患儿出血程度显著优于治疗前,差异具有统计学意义(P<0.05)。治疗后,患儿VAS评分为(1.15±0.11)分,显著低于治疗前的(3.26±0.68)分,差异具有统计学意义(P<0.05)。治疗后,患儿环境、社会、心理、生理生活质量评分分别为(89.62±6.84)、(91.52±7.14)、(91.48±7.09)、(90.05±7.01)分,均显著高于治疗前的(62.85±5.14)、(61.05±5.08)、(63.74±5.34)、(62.89±5.16)分,差异均具有统计学意义(P<0.05)。结论小剂量凝血因子输注可有效减轻血友病急性关节出血患儿出血情况与疼痛程度,提升生活质量,效果显著,值得借鉴。
Objective To analyze the efficacy of low-dose coagulation factor infusion on acute joint bleeding in hemophilia. Methods A total of 85 hemophilia children with acute joint bleeding all were treated with low-dose coagulation factor infusion. The bleeding degree, visual analogue scale(VAS) score and quality of life were compared before treatment and 1 year after treatment. Results Patients had significantly better bleeding degree after treatment than those before treatment, and the difference was statistically significant(P<0.05). After treatment, patients had significantly lower VAS score as(1.15±0.11) points than(3.26±0.68) points before treatment, and the difference was statistically significant(P<0.05). After treatment, patients had significantly higher environmental, social, psychological and physiological quality of life score respectively as(89.62±6.84),(91.52±7.14),(91.48±7.09) and(90.05±7.01) points than(62.85±5.14),(61.05±5.08),(63.74±5.34) and(62.89±5.16) points before treatment, and their difference was statistically significant(P<0.05). Conclusion Low-dose coagulation factor infusion shows remarkable effect in effectively reducing bleeding and pain degree of hemophilia children with acute joint bleeding and improving quality of life. It is worthy of reference.
Objective To analyze the efficacy of low-dose coagulation factor infusion on acute joint bleeding in hemophilia. Methods A total of 85 hemophilia children with acute joint bleeding all were treated with low-dose coagulation factor infusion. The bleeding degree, visual analogue scale(VAS) score and quality of life were compared before treatment and 1 year after treatment. Results Patients had significantly better bleeding degree after treatment than those before treatment, and the difference was statistically significant(P<0.05). After treatment, patients had significantly lower VAS score as(1.15±0.11) points than(3.26±0.68) points before treatment, and the difference was statistically significant(P<0.05). After treatment, patients had significantly higher environmental, social, psychological and physiological quality of life score respectively as(89.62±6.84),(91.52±7.14),(91.48±7.09) and(90.05±7.01) points than(62.85±5.14),(61.05±5.08),(63.74±5.34) and(62.89±5.16) points before treatment, and their difference was statistically significant(P<0.05). Conclusion Low-dose coagulation factor infusion shows remarkable effect in effectively reducing bleeding and pain degree of hemophilia children with acute joint bleeding and improving quality of life. It is worthy of reference.
引文
[1]李红艺.小剂量凝血因子输注治疗血友病急性关节出血的疗效研究.中国校医, 2017, 31(12):932.
[2]方拥军,洪恺.关节出血对血友病关节的影响.中国实用儿科杂志, 2017, 32(1):70-75.
[3]冯宾,翁习生,林进,等.血友病性骨关节病变的外科治疗策略.中华骨科杂志, 2016, 36(7):413-421.
[4]门亚勋,贺尧,曹万全,等.凝血因子替代疗法下血友病A患者行THA 1例报告.实用骨科杂志, 2017, 23(7):668-670.
[5]马山,张振,高超.人凝血酶原复合物治疗乙型血友病的有效性和安全性评价.中国输血杂志, 2016, 29(9):945-947.
[6]刘国青,陈振萍,吴润晖.血友病关节病变与炎症因子关系的研究进展.血栓与止血学, 2016, 22(6):718-720.
[7]杨新平,敖志文,彭弘,等.小剂量重组人凝血因子Ⅷ治疗血友病甲外伤后蛛网膜下腔出血并硬膜下血肿1例.江西医药,2017, 52(5):426-427.
[8]郑冬丽.反复输注血液制品对血友病抗体及凝血因子活性的影响.中国实用医刊, 2015, 20(13):21-22.
[9]张静,严媚.重型血友病A患儿重组人凝血因子Ⅷ短期预防治疗的研究.浙江临床医学, 2017, 19(7):1220-1221.
[10]张润花,杨时佳,吴思静,等.重组凝血因子Ⅶa治疗获得性血友病A合并严重出血的疗效观察.内科急危重症杂志,2015, 21(4):316-317.
[11]胡政斌,孙新,何丽雅.遗传因素与血友病A凝血因子抑制物产生的研究进展.中国实验血液学杂志, 2017, 25(3):957-960.
[12]王武超,郭杨.小剂量凝血因子输注治疗血友病急性关节出血的疗效研究.中国急救医学, 2013, 33(s1):7-9.
[13]傅玲玲,吴润晖.治疗模式与血友病颅内出血综述.中国小儿血液与肿瘤杂志, 2015, 20(1):47-49.
[14]王迪.低剂量重组人凝血因子Ⅷ预防治疗儿童血友病A的效果评价.中国现代医药杂志, 2016, 18(5):86-88.
[15]张建华,董春霞,张爱荣,等.血浆源性人凝血因子Ⅷ治疗血友病A有效性和安全性多中心Ⅲ期临床研究.中华内科杂志,2016, 55(8):624-627.
[16]肖娟,赵永强,李魁星,等.重型血友病A患儿低剂量预防治疗血浆凝血因子Ⅷ谷浓度的检测.血栓与止血学, 2016, 22(1):61-65.
[2]方拥军,洪恺.关节出血对血友病关节的影响.中国实用儿科杂志, 2017, 32(1):70-75.
[3]冯宾,翁习生,林进,等.血友病性骨关节病变的外科治疗策略.中华骨科杂志, 2016, 36(7):413-421.
[4]门亚勋,贺尧,曹万全,等.凝血因子替代疗法下血友病A患者行THA 1例报告.实用骨科杂志, 2017, 23(7):668-670.
[5]马山,张振,高超.人凝血酶原复合物治疗乙型血友病的有效性和安全性评价.中国输血杂志, 2016, 29(9):945-947.
[6]刘国青,陈振萍,吴润晖.血友病关节病变与炎症因子关系的研究进展.血栓与止血学, 2016, 22(6):718-720.
[7]杨新平,敖志文,彭弘,等.小剂量重组人凝血因子Ⅷ治疗血友病甲外伤后蛛网膜下腔出血并硬膜下血肿1例.江西医药,2017, 52(5):426-427.
[8]郑冬丽.反复输注血液制品对血友病抗体及凝血因子活性的影响.中国实用医刊, 2015, 20(13):21-22.
[9]张静,严媚.重型血友病A患儿重组人凝血因子Ⅷ短期预防治疗的研究.浙江临床医学, 2017, 19(7):1220-1221.
[10]张润花,杨时佳,吴思静,等.重组凝血因子Ⅶa治疗获得性血友病A合并严重出血的疗效观察.内科急危重症杂志,2015, 21(4):316-317.
[11]胡政斌,孙新,何丽雅.遗传因素与血友病A凝血因子抑制物产生的研究进展.中国实验血液学杂志, 2017, 25(3):957-960.
[12]王武超,郭杨.小剂量凝血因子输注治疗血友病急性关节出血的疗效研究.中国急救医学, 2013, 33(s1):7-9.
[13]傅玲玲,吴润晖.治疗模式与血友病颅内出血综述.中国小儿血液与肿瘤杂志, 2015, 20(1):47-49.
[14]王迪.低剂量重组人凝血因子Ⅷ预防治疗儿童血友病A的效果评价.中国现代医药杂志, 2016, 18(5):86-88.
[15]张建华,董春霞,张爱荣,等.血浆源性人凝血因子Ⅷ治疗血友病A有效性和安全性多中心Ⅲ期临床研究.中华内科杂志,2016, 55(8):624-627.
[16]肖娟,赵永强,李魁星,等.重型血友病A患儿低剂量预防治疗血浆凝血因子Ⅷ谷浓度的检测.血栓与止血学, 2016, 22(1):61-65.